Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.

NCT04326920 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT04326920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04326920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.
Lead sponsor
University Hospital, Ghent
Phase
Phase 4
Overall status
Completed
Start date
March 24, 2020
Completion date
February 26, 2021
Enrollment
87 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19